Dr. Vivek Paulbuddhe, Dr. Ronel Soibam, Dr. Satyen Deka, Dr. Diva Kant Misra
Aim: To investigate the efficacy and safety profile of intravitreal dexamethasone implant in a patients with resistant diabetic macular edema.
Methods: 36 eyes of 27 patients were included in this 6 month,prospective interventional clinical study. Main observed outcomes were the changes between initial and monthly (1,3,6 months) visits with respect to best corrected visual acuity(BCVA), central macular thickness and intraocular pressure (IOP). Patients included were >30 years of age with BCVA better than 20/200 & had central foveal thickness of 0.300 mm and were nonresponsive to previously administered 2 consecutive monthly intravitreal injections of 1.25 mg bevacizumab.Administration of intravitreal dexamethasone implant was performed at baseline, and patients were followed-up at 1,3,6 months.
Conclusion: Dexamethasone intravitreal implant can serve as an effective option for the treatment of resistant DME, where anti-VEGF injections are not able to produce desired effects.